Literature DB >> 2118709

The long-term effects of estradiol implant therapy for the treatment of premenstrual syndrome.

N R Watson1, J W Studd, M Savvas, R J Baber.   

Abstract

Fifty patients receiving estradiol implants for long-term treatment of premenstrual syndrome were studied over 5.6 years (range 2-8 years). There was a continued beneficial response to treatment in all symptoms, varying between 74% for bloating and 96% for depression. Menstrual cycle control improved in 31 patients and periods were less painful in 30 patients. Cyclical progestogenic symptoms occurred in 58% of patients. These were partially relieved by alterations in dose, type and duration of progestogen treatment but in 7 patients the symptoms remained severe. Eight patients had a hysterectomy during treatment; 5 for continuing progestogenic symptoms, 1 for prolapse and 2 for prolonged menstrual bleeding despite adequate progestogen therapy. Attempts to reduce the dose of progestogen led to cystic hyperplasia in 4 patients. This was treated by hysterectomy in 2 patients and corrected with two 21-day courses of progestogen in the other 2. Uterine enlargement with a mean weight of 133 g (125-145 g) associated with myometrial hypertrophy occurred in all 8 hysterectomy patients. There were no complications form venous thrombosis, pulmonary embolus, breast disease or atypical endometrial hyperplasia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2118709     DOI: 10.3109/09513599009012326

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  9 in total

Review 1.  Helping women with premenstrual syndrome.

Authors:  P M O'Brien
Journal:  BMJ       Date:  1993-12-04

Review 2.  Prevention and treatment of menstrual migraine.

Authors:  E Anne MacGregor
Journal:  Drugs       Date:  2010-10-01       Impact factor: 9.546

Review 3.  The role of hormones and hormonal treatments in premenstrual syndrome.

Authors:  Torbjörn Bäckström; Lotta Andreen; Vita Birzniece; Inger Björn; Inga-Maj Johansson; Maud Nordenstam-Haghjo; Sigrid Nyberg; Inger Sundström-Poromaa; Göran Wahlström; Mingde Wang; Di Zhu
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 4.  A reproductive subtype of depression: conceptualizing models and moving toward etiology.

Authors:  Jennifer L Payne; Jennifer Teitelbaum Palmer; Hadine Joffe
Journal:  Harv Rev Psychiatry       Date:  2009       Impact factor: 3.732

Review 5.  Update on research and treatment of premenstrual dysphoric disorder.

Authors:  Joanne Cunningham; Kimberly Ann Yonkers; Shaughn O'Brien; Elias Eriksson
Journal:  Harv Rev Psychiatry       Date:  2009       Impact factor: 3.732

6.  Premenstrual syndrome.

Authors:  Kimberly Ann Yonkers; P M Shaughn O'Brien; Elias Eriksson
Journal:  Lancet       Date:  2008-04-05       Impact factor: 79.321

7.  Reproductive hormonal treatments for mood disorders in women.

Authors:  Peter J Schmidt; David R Rubinow
Journal:  Dialogues Clin Neurosci       Date:  2002-06       Impact factor: 5.986

8.  A study of the referral patterns and therapeutic experiences of 100 women attending a specialist premenstrual syndrome clinic.

Authors:  A T Leather; E F Holland; G D Andrews; J W Studd
Journal:  J R Soc Med       Date:  1993-04       Impact factor: 18.000

9.  Treatment of premenstrual dysphoric disorder (PMDD) with a novel formulation of drospirenone and ethinyl estradiol.

Authors:  Domenico De Berardis; Nicola Serroni; Rosa Maria Salerno; Filippo Maria Ferro
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.